Author: Mark Henderson

CCA report fuses research and industrial R&D data to expose weak linkages between home-grown S&T and wealth creation

Canadian science and technology and industrial R&D are faced with a growing risk of becoming branch plants of research, innovation and competitiveness for other countries. While not new, this conclusion reached by an expert panel tasked to examine the issue that says the severity and urgency of the situation are increasing due to rapidly evolving global trends, the “start and sell” mentality of many tech entrepreneurs and the ecosystem damage inflicted between 2006 and 2015.

Read More

Strategic direction and a re-balancing of research types essential for improving Canada’s innovation performance – McDougall

Canada must re-balance public investments that currently overemphasize fundamental research and provide high-level direction to increase the uptake and application of innovation, including offering experiential learning and professional development for key players in the innovation ecosystem, says a former president of the National Research Council (NRC).

Read More

Pharmaceutical R&D spending remains far below industry’s 10% commitment – PMPRB report

Another year of less-than-impressive R&D spending by the pharmaceutical industry has re-ignited the annual sparing match between industry and the organization that compiles the data. The Patented Medicines Prices Review Board (PMPRB) reports that companies belonging to Innovative Medicines Canada (IMC – formerly Rx&D) spent $770 million on R&D in 2016 or 4.9% of its $15.6 billion in sales – a ratio unchanged from 2015.

Read More